• 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 2
    Neville BW,Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002; 52: 195215.
  • 3
    Bernardini G,Ribatti D,Spinetti G,Morbidelli L,Ziche M,Santoni A,Capogrossi MC,Napolitano M. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273: 83101.
  • 4
    Buck MB,Knabbe C. TGF-beta signaling in breast cancer. Ann NY Acad Sci 2006; 1089: 11926.
  • 5
    Inoue J,Gohda J,Akiyama T,Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci 2007; 98: 26874.
  • 6
    Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21: 42556.
  • 7
    Fichtner-Feigl S,Strober W,Kawakami K,Puri RK,Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99106.
  • 8
    Joshi BH,Plautz GE,Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000; 60: 116872.
  • 9
    Kawakami M,Kawakami K,Kasperbauer JL,Hinkley LL,Tsukuda M,Strome SE,Puri RK. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003; 9: 63818.
  • 10
    Husain SR,Puri RK. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 2000; 95: 350613.
  • 11
    Kioi M,Kawakami M,Shimamura T,Husain SR,Puri RK. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006; 107: 140718.
  • 12
    Kioi M,Husain SR,Croteau D,Kunwar S,Puri RK. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat 2006; 5: 23950.
  • 13
    Minn AJ,Gupta GP,Siegel PM,Bos PD,Shu W,Giri DD,Viale A,Olshen AB,Gerald WL,Massagué J. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 51824.
  • 14
    Puri RK,Leland P,Obiri NI,Husain SR,Kreitman RJ,Haas GP,Pastan I,Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996; 87: 43339.
  • 15
    Kunwar S,Chang SM,Prados MD,Berger MS,Sampson JH,Croteau D,Sherman JW,Grahn AY,Shu VS,Dul JL,Husain SR,Joshi BH, et al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 2006; 20: E15.
  • 16
    Joshi BH,Kawakami K,Leland P,Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002; 8: 194856.
  • 17
    McGuire WP,Hoskins WJ,Brady MF,Kucera PR,Partridge EE,Look KY,Clarke-Pearson DL,Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 16.
  • 18
    Haddad R,Colevas AD,Tishler R,Busse P,Goguen L,Sullivan C,Norris CM,Lake-Willcutt B,Case MA,Costello R,Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003; 97: 4128.
  • 19
    Okami K,Sakai A,Onuki J,Odagiri K,Takahashi M. Two patients with distant metastases from head and neck squamous cell carcinomas successfully treated with docetaxel and cisplatin. Gan To Kagaku Ryoho 2003; 30: 959.
  • 20
    Schiff PB,Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 15615.
  • 21
    Kioi M,Kawakami K,Puri RK. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 2004; 10: 62318.
  • 22
    Kioi M,Seetharam S,Puri RK. N-linked glycosylation of IL-13R alpha2 is essential for optimal IL-13 inhibitory activity. FASEB J 2006; 20: 237880.
  • 23
    Murata T,Obiri NI,Debinski W,Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997; 238: 904.
  • 24
    Chou TC,Tan QH,Sirotnak FM. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 1993; 31: 25964.
  • 25
    Zurawski SM,Chomarat P,Djossou O,Bidaud C,McKenzie AN,Miossec P,Banchereau J,Zurawski G. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995; 270: 1386978.
  • 26
    Roe T,Reynolds TC,Yu G,Brown PO. Integration of murine leukemia virus DNA depends on mitosis. Embo J 1993; 12: 2099108.
  • 27
    Andreadis ST,Brott D,Fuller AO,Palsson BO. Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours. J Virol 1997; 71: 75418.
  • 28
    Kim ES,Glisson BS. Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res 2003; 114: 295314.
  • 29
    Tsao AS,Garden AS,Kies MS,Morrison W,Feng L,Lee JJ,Khuri F,Zinner R,Myers J,Papadimitrakopoulou V,Lewin J,Clayman GL, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2006; 24: 41639.
  • 30
    Chiappori AA,Ellis PM,Hamm JT,Bitran JD,Eiseman I,Lovalvo J,Burnett D,Olson S,Lenehan P,Zinner RG. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006; 1: 10109.
  • 31
    Vokes E,Herbst R,Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol 2006; 4: 112.
  • 32
    Shin DM,Glisson BS,Khuri FR,Lippman SM,Ginsberg L,Diaz EJr,Papadimitrakopoulou V,Feng L,Francisco M,Garden A,Kies MS,Myers J, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002; 95: 32230.
  • 33
    Specenier P,Vermorken JB. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 2007; 19: 195201.
  • 34
    Husain SR,Oshima Y,Gokhale PC,Kasid UN,Puri RK. Pre-clinical safety evaluation of recombinant interleukin 13-pseudomonas exotoxin (IL13-PE38) for targeted cancer therapy. Proc Am Assoc Cancer Res 2003; 1st Ed: Abstract #5484, p 1257.